866-997-4948(US-Canada Toll Free)

Uterine Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Cancer

No. of Pages : 308 Pages


Global Markets Directs, \'Uterine Cancer - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. 

Uterine Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Uterine Cancer.
  • A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Uterine Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Uterine Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Uterine Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Uterine Cancer 11
Uterine Cancer Therapeutics under Development by Companies 13
Uterine Cancer Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Uterine Cancer Therapeutics - Products under Development by Companies 25
Uterine Cancer Therapeutics - Products under Investigation by Universities/Institutes 30
Companies Involved in Uterine Cancer Therapeutics Development 32
Bristol-Myers Squibb Company 32
Photocure ASA 33
Helix BioPharma Corp. 34
Sanofi-Aventis 35
AstraZeneca PLC 36
GlaxoSmithKline plc 37
Genentech, Inc. 38
Gilead Sciences, Inc. 39
Merck & Co., Inc. 40
Amorfix Life Sciences Ltd. 41
MediGene AG 42
Nanotherapeutics, Inc. 43
Novartis AG 44
Chong Kun Dang Pharmaceutical 45
Eisai Co., Ltd. 46
Pfizer Inc. 47
Taiho Pharmaceutical Co., Ltd. 48
Zeria Pharmaceutical Co Ltd 49
CEL-SCI Corporation 50
Advaxis, Inc. 51
3SBio Inc. 52
Neogenix Oncology Corporation 53
EntreMed, Inc. 54
AEterna Zentaris Inc. 55
Critical Outcome Technologies Inc. 56
Dendreon Corporation 57
Transgene SA 58
Innocell Corporation 59
RXi Pharmaceuticals Corporation 60
Antigen Express, Inc. 61
Oryzon 62
Shantha Biotechnics Limited 63
Nutri Pharma ASA 64
Acceleron Pharma, Inc. 65
Med Discovery SA 66
Priaxon AG 67
Dafra Pharma International Ltd. 68
ApoImmune, Inc. 69
Azaya Therapeutics, Inc. 70
Genexine Co., Ltd. 71
Esperance Pharmaceuticals, Inc. 72
BT PHARMA 73
Genetic Immunity, LLC 74
Sirnaomics, Inc. 75
EndoCeutics, Inc. 76
Advanced Cancer Therapeutics 77
Anaphore, Inc. 78
Cancer Therapeutics CRC Pty Ltd 79
Aragon Pharmaceuticals, Inc. 80
Xenova Group plc 81
Mycenax Biotech Inc. 82
EyeGene, Inc. 83
Vaccibody AS 84
ISA Pharmaceuticals B.V. 85
Coridon Pty Ltd 86
Uterine Cancer - Therapeutics Assessment 87
Assessment by Monotherapy Products 87
Assessment by Combination Products 88
Assessment by Route of Administration 89
Assessment by Molecule Type 92
Drug Profiles 95
AEZS-108 - Drug Profile 95
lenvatinib - Drug Profile 97
RG-7422 - Drug Profile 100
PF-05212384 - Drug Profile 102
ridaforolimus - Drug Profile 103
MKC-1 - Drug Profile 107
dalantercept - Drug Profile 109
MDRG-01 - Drug Profile 111
docetaxel - Drug Profile 112
Leukocyte Interleukin Injection - Drug Profile 114
SAR-566658 - Drug Profile 116
Drug Targeting Carbonic Anhydrase IX - Drug Profile 118
fulvestrant - Drug Profile 119
everolimus - Drug Profile 121
iniparib - Drug Profile 124
interferon alpha-2b - Drug Profile 126
COTI-2 - Drug Profile 127
SSS-08 Vaccine - Drug Profile 130
mapatumumab - Drug Profile 131
ADXS-HPV - Drug Profile 134
ApoVax-104-HPV - Drug Profile 137
EP-100 - Drug Profile 138
dovitinib lactate - Drug Profile 140
ProCervix - Drug Profile 142
Z-100 - Drug Profile 143
celecoxib - Drug Profile 144
cetuximab + [cisplatin] + Radiation Therapy - Drug Profile 145
Triapine - Drug Profile 146
human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Drug Profile 148
Angiotensin 1-7 - Drug Profile 150
cetuximab + [cisplatin] - Drug Profile 152
HPV Vaccine - Drug Profile 153
irinotecan hydrochloride + [cisplatin] - Drug Profile 154
buparlisib - Drug Profile 155
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 158
Multimeric-L2 Protein Vaccine - Drug Profile 159
nimotuzumab - Drug Profile 160
nimotuzumab - Drug Profile 163
GSK-2141795 + trametinib - Drug Profile 166
nimotuzumab + Radiation Therapy - Drug Profile 167
HLA-A-0201 Restricted Specific Epitope Peptides - Drug Profile 169
HLA-A 2402 Restricted Specific Epitope Peptide - Drug Profile 170
TG-4001 - Drug Profile 171
COTI-2 + [paclitaxel albumin-bound] - Drug Profile 172
AEZS-132 - Drug Profile 174
ixabepilone - Drug Profile 175
vandetanib + [carboplatin] + [gemcitabine] - Drug Profile 177
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 179
cetuximab + [cisplatin] + Radiation Therapy - Drug Profile 180
Adva-27a - Drug Profile 181
nintedanib - Drug Profile 183
mapatumumab + [cisplatin] + Radiotherapy - Drug Profile 184
artesunate - Drug Profile 185
X-480 - Drug Profile 186
EP-200 - Drug Profile 187
HupaDerm Vaccine - Drug Profile 188
NEO-201 - Drug Profile 189
CIGB-300 - Drug Profile 191
nimotuzumab + [cisplatin] + [vinorelbine tartrate] - Drug Profile 193
(tegafur + gimeracil + oteracil potassium) - Drug Profile 195
RBT-201 - Drug Profile 198
hexaminolevulinate hydrochloride - Drug Profile 199
Squamous Antibodies - Drug Profile 200
trastuzumab + [carboplatin] + [paclitaxel] - Drug Profile 202
cidofovir - Drug Profile 204
ARGX-109 - Drug Profile 205
AEH-10p - Drug Profile 206
Folate Binding Protein E39 Targeted Vaccine - Drug Profile 207
AAVLP Program - Drug Profile 208
HPV-SLP Vaccine - Drug Profile 209
Cervlysis - Drug Profile 210
ADXS-HPV + [cisplatin] - Drug Profile 211
EG-HPV - Drug Profile 212
Human Papillomavirus Vaccine - Drug Profile 213
temsirolimus + trebananib - Drug Profile 214
First Generation Bivalent HPV Vaccine - Drug Profile 215
mapatumumab + (cisplatin) + Radiation Therapy - Drug Profile 216
E39 Peptide Vaccine - Drug Profile 217
TP-0227 - Drug Profile 218
HPV Vaccine - Drug Profile 219
Monoclonal Antibody For Endometrial Cancer - Drug Profile 220
Drug Targeting PRMT5 - Drug Profile 221
CKD-12201 - Drug Profile 222
acolbifene hydrochloride - Drug Profile 223
GX-188E - Drug Profile 224
Anti-Fas - Drug Profile 225
nedaplatin + [paclitaxel albumin-bound] - Drug Profile 226
E6-p53 Inhibitors - Drug Profile 227
ONCO-101 - Drug Profile 228
CX-99 - Drug Profile 229
VB-1016 - Drug Profile 230
EDA-HPVE7 - Drug Profile 231
ARN-912 - Drug Profile 233
STP-909 - Drug Profile 234
TA-HPV Vaccine - Drug Profile 235
Bromodomain Inhibitors - Drug Profile 236
AEZS-138 - Drug Profile 237
Tumour Anti Invasive Compounds - Drug Profile 238
Platinum Based Compounds - Drug Profile 239
Uterine Cancer Therapeutics - Drug Profile Updates 240
Uterine Cancer Therapeutics - Discontinued Products 286
Uterine Cancer Therapeutics - Dormant Products 287
Uterine Cancer - Product Development Milestones 293
Featured News & Press Releases 293

Appendix 300
Methodology 300
Coverage 300
Secondary Research 300
Primary Research 300
Expert Panel Validation 300
Contact Us 301
Disclaimer 301

List of Table


Number of Products Under Development for Uterine Cancer, H1 2013 18
Products under Development for Uterine Cancer - Comparative Analysis, H1 2013 19
Number of Products under Development by Companies, H1 2013 21
Number of Products under Development by Companies, H1 2013 (Contd..1) 22
Number of Products under Development by Companies, H1 2013 (Contd..2) 23
Number of Products under Development by Companies, H1 2013 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2013 26
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2013 37
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 38
Bristol-Myers Squibb Company, H1 2013 39
Photocure ASA, H1 2013 40
Helix BioPharma Corp., H1 2013 41
Sanofi-Aventis, H1 2013 42
AstraZeneca PLC, H1 2013 43
GlaxoSmithKline plc, H1 2013 44
Genentech, Inc., H1 2013 45
Gilead Sciences, Inc., H1 2013 46
Merck & Co., Inc., H1 2013 47
Amorfix Life Sciences Ltd., H1 2013 48
MediGene AG, H1 2013 49
Nanotherapeutics, Inc., H1 2013 50
Novartis AG, H1 2013 51
Chong Kun Dang Pharmaceutical, H1 2013 52
Eisai Co., Ltd., H1 2013 53
Pfizer Inc., H1 2013 54
Taiho Pharmaceutical Co., Ltd., H1 2013 55
Zeria Pharmaceutical Co Ltd, H1 2013 56
CEL-SCI Corporation, H1 2013 57
Advaxis, Inc., H1 2013 58
3SBio Inc., H1 2013 59
Neogenix Oncology Corporation, H1 2013 60
EntreMed, Inc., H1 2013 61
AEterna Zentaris Inc., H1 2013 62
Critical Outcome Technologies Inc., H1 2013 63
Dendreon Corporation, H1 2013 64
Transgene SA, H1 2013 65
Innocell Corporation, H1 2013 66
Antigen Express, Inc., H1 2013 68
Oryzon, H1 2013 69
Shantha Biotechnics Limited, H1 2013 70
Nutri Pharma ASA, H1 2013 71
Acceleron Pharma, Inc., H1 2013 72
Med Discovery SA, H1 2013 73
Priaxon AG, H1 2013 74
Dafra Pharma International Ltd., H1 2013 75
ApoImmune, Inc., H1 2013 76
Azaya Therapeutics, Inc., H1 2013 77
Genexine Co., Ltd., H1 2013 78
Esperance Pharmaceuticals, Inc., H1 2013 79
BT PHARMA, H1 2013 80
Genetic Immunity, LLC, H1 2013 81
Sirnaomics, Inc., H1 2013 82
EndoCeutics, Inc., H1 2013 83
Advanced Cancer Therapeutics, H1 2013 84
Anaphore, Inc., H1 2013 85
Cancer Therapeutics CRC Pty Ltd, H1 2013 86
Aragon Pharmaceuticals, Inc., H1 2013 87
Xenova Group plc, H1 2013 88
Mycenax Biotech Inc., H1 2013 89
EyeGene, Inc., H1 2013 90
Vaccibody AS, H1 2013 91
Coridon Pty Ltd, H1 2013 93
Assessment by Monotherapy Products, H1 2013 94
Assessment by Combination Products, H1 2013 95
Assessment by Stage and Route of Administration, H1 2013 98
Assessment by Stage and Molecule Type, H1 2013 101
Uterine Cancer Therapeutics - Drug Profile Updates 247
Uterine Cancer Therapeutics - Discontinued Products 293
Uterine Cancer Therapeutics - Dormant Products 294
Uterine Cancer Therapeutics - Dormant Products (Contd..1) 295
Uterine Cancer Therapeutics - Dormant Products (Contd..2) 296
Uterine Cancer Therapeutics - Dormant Products (Contd..3) 297
Uterine Cancer Therapeutics - Dormant Products (Contd..4) 298
Uterine Cancer Therapeutics - Dormant Products (Contd..5) 299

List of Chart


Number of Products under Development for Uterine Cancer, H1 2013 18
Products under Development for Uterine Cancer - Comparative Analysis, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 25
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 94
Assessment by Combination Products, H1 2013 95
Assessment by Route of Administration, H1 2013 96
Assessment by Stage and Route of Administration, H1 2013 97
Assessment by Molecule Type, H1 2013 99
Assessment by Stage and Molecule Type, H1 2013 100

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *